ACC/AHA/ASE/ASNC/HRS/IAC/Mended Hearts/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 Health Policy Statement on Use of Noninvasive Cardiovascular Imaging A Report of the American College of Cardiology Clinical Quality Committee by Mark, Daniel B. et al.
Journal of the American College of Cardiology Vol. 63, No. 7, 2014
© 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00HEALTH POLICY STATEMENT
ACC/AHA/ASE/ASNC/HRS/IAC/Mended Hearts/
NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI
2014 Health Policy Statement on Use of
Noninvasive Cardiovascular Imaging
A Report of the American College of Cardiology Clinical Quality Committee
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.002R
D
R
M
J
S
K
V
F
M
G
L
t
i

#
N
s
#Writing
Committee
MembersThe American College of
follows: Mark DB, AndersoDaniel B. Mark, MD, MPH, FACC, FAHA,
Chair*
Jeffrey L. Anderson, MD, FACC, FAHA,
FHRS†
Jeffrey A. Brinker, MD, FACC, FSCAI‡
James A. Brophy, MD, FACC*
Donald E. Casey, JR, MD, MPH, MBA,
FACP, FAHA§
ussell R. Cross, MD, FACC*
aniel Edmundowicz, MD, FACC
ory Hachamovitch, MD, FACC¶
ark A. Hlatky, MD, FACC, FAHA#
ill E. Jacobs, MD, FACR, FNASCI**
uzette Jaskie*
evin G. Kett, MD, FACC††
inay Malhotra, MBBS, FACC, FAHA,
FSCCT‡‡
rederick A. Masoudi, MD, MSPH, FACC,Cardiology requests that this document be cited as
n JL, Brinker JA, Brophy JM, Casey DE Jr., Cross elsevier-mateichael V. McConnell, MD, MSEE, FACC,
FAHA§§
eoffrey D. Rubin, MD, FNASCI 
eslee J. Shaw, PHD, FACC, FAHA,
FASNC¶¶
M. Eugene Sherman, MD, FACC*
Steve Stanko, MBA##
R. Parker Ward, MD, FACC, FASE***
*American College of Cardiology Representative, †Heart Rhythm Society
Representative, ‡Society for Cardiovascular Angiography and Interven-
ions Representative, ¶Society of Nuclear Medicine and Molecular Imag-
ng Representative, §American College of Physicians Representative,
Society of Atherosclerosis Imaging and Prevention Representative,
American Heart Association Representative, **Radiological Society of
orth America Representative, ††Intersocietal Accreditation Commis-
sion Representative, ‡‡Society of Cardiovascular Computed Tomography
Representative, §§Society for Cardiovascular Magnetic Resonance Repre-
sentative, North American Society for Cardiovascular Imaging Repre-
entative, ¶¶American Society of Nuclear Cardiology Representative,
#Mended Hearts Consumer Advocate, Patient Representative, ***Amer-FAHA* ican Society of Echocardiography Representative
Author Recusals: Writing committee members are required to recuse themselves from
voting on sections to which their specific relationship with industry and other entities
may apply; see Appendix 1 for recusal information.
This document was approved by the American College of Cardiology Foundation
Board of Trustees in August 2013 and endorsed by the governing bodies of the
American Heart Association (AHA), American Society of Echocardiography (ASE),
American Society of Nuclear Cardiology (ASNC), Heart Rhythm Society (HRS),
Intersocietal Accreditation Commission (IAC), Mended Hearts, North American
Society for Cardiovascular Imaging (NASCI), Radiological Society of North America
(RSNA), Society of Atherosclerosis Imaging and Prevention (SAIP), Society for
Cardiovascular Angiography and Interventions Foundation (SCAI), Society of
Cardiovascular Computed Tomography (SCCT), Society for Cardiovascular Mag-
netic Resonance (SCMR), and the Society of Nuclear Medicine and Molecular
Imaging (SNMMI) in January 2014. For the purpose of complete transparency,
disclosure information for the ACCF Board of Trustees, the board of the convening
organization of this document, is available at: http://www.cardiosource.org/ACC/
About-ACC/Leadership/Officers-and-Trustees.aspx. ACC board members with rel-
evant relationships with industry to the document may review and comment on the
document but may not vote on approval.
RR, Edmundowicz D, Hachamovitch R, Hlatky MA, Jacobs JE, Jaskie S, Kett
KG, Malhotra V, Masoudi FA, McConnell MV, Rubin GD, Shaw LJ, Sherman
ME, Stanko S, Ward RP. ACC/AHA/ASE/ASNC/HRS/IAC/Mended Hearts/
NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 health policy state-
ment on use of noninvasive cardiovascular imaging: a report of the American
College of Cardiology Clinical Quality Committee. J Am Coll Cardiol 2014;63:
698 –721.
Copies: This document is available on the World Wide Web sites of the American
College of Cardiology (www.cardiosource.org), the AHA (www.heart.org), ASE
(www.asecho.org), ASNC (www.asnc.org), HRS (www.hrsonline.org), IAC (www.
iaconlineaccreditation.org), Mended Hearts (mendedhearts.org), NASCI (www.nasci.
org), RSNA (www.rsna.org), SAIP (www.sai-p.org), SCAI (www.scai.org/
Default.aspx), SCCT (www.scct.org), and the SCMR (scmr.org). For copies of this
document, please contact Elsevier Inc. Reprint Department, fax 212-633-3820,
e-mail reprints@elsevier.com.
Permissions: Modification, alteration, enhancement, and/or distribution of this
document are not permitted without the express permission of the American
College of Cardiology Foundation. Requests may also be completed online via the
Elsevier site (http://www.elsevier.com/authors/obtainingpermission-to-re-use-rial).
699JACC Vol. 63, No. 7, 2014 Mark et al.
February 25, 2014:698–721 HPS on Use of Noninvasive CV ImagingACC Clinical
Quality
Committee
Members
Joseph P. Drozda, JR, MD, FACC, Chair
Deepak L. Bhatt, MD, MPH, FACC
Joseph G. Cacchione, MD, FACC
Blair D. Erb, Jr, MD, FACC
Thomas A. Haffey, DO, FACC
Robert A. Harrington, MD, FACC†††
Jerry D. Kennett, MD, MACC
Richard J. Kovacs, MD, FACC
Harlan M. Krumholz, MD, SM, FACC
Frederick A. Masoudi, MD, MSPH, FACC
Eric D. Peterson, MD, MPH, FACC
Athena Poppas, MD, FACC
Michael J. Reardon, MD, FACC
David J. Sahn, MD, MACC
Mark L. Sanz, MD, FACC†††
David M. Shahian, MD, FACC†††
Eric Stecker, MD, FACC
Judy Tingley, RN
Mary Norine Walsh, MD, FACC
W. Douglas Weaver, MD, MACC
John R. Windle, MD, FACC
†††Former Clinical Quality Committee Representative during this
writing effort.TABLE OF CONTENTS
Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .699
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .700
1.1. Document Development Process . . . . . . . . . . . . . . . . .700
1.1.1. Writing Committee Organization . . . . . . . . . . . . . .700
1.1.2. Policy Statement Development . . . . . . . . . . . . . . . . .700
2. Purpose of This Health Policy Statement:
Overview of the Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .700
2.1. Current Understanding of Patterns of
Cardiovascular Diagnostic Imaging Use . . . . . . . . . .701
2.2. Drivers of Physician Use of Diagnostic Testing. . . . . .701
2.3. Imaging and Patient Safety:
The Issue of Cumulative Diagnostic
Radiation Exposure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .702
2.4. Overview of What Follows . . . . . . . . . . . . . . . . . . . . . . . . .702
3. Improving Imaging Use: Conceptual Overview . . . . .703
4. Improving Imaging Use: Approaches and Tools . . . .703
4.1. Technology Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . .704
4.2. Appropriate Use of Testing . . . . . . . . . . . . . . . . . . . . . . . .704
4.3. Quality Framework for Diagnostic Imaging . . . . . .706
4.3.1. Quality Improvement of Imaging:
Laboratory Accreditation . . . . . . . . . . . . . . . . . . . . . . .706
4.3.2. Quality Improvement of Imaging:
Physician Certification and Credentialing . . . . . .707
4.3.3. Quality Improvement of Imaging:
Integration of Care and Accountability. . . . . . . . .707
5. Identifying and Reducing Underuse of
Cardiac Imaging. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7086. Identifying and Reducing Overuse of
Cardiac Imaging. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .709
6.1. Payer Efforts to Control Imaging Costs:
Administrative Efforts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .709
6.2. Payer Efforts to Control Imaging Costs:
Use of Payment Reforms . . . . . . . . . . . . . . . . . . . . . . . . . .710
6.3. Appropriate Use Criteria . . . . . . . . . . . . . . . . . . . . . . . . . . .710
6.4. Clinical Decision Support Tools . . . . . . . . . . . . . . . . . . .710
6.5. Performance Measurement for Cardiac Imaging . .712
6.6. Physician Professional Organization Initiatives . . .712
7. Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .712
8. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .713
Appendix 1: Author Relevant Relationships With
Industry and Other Entities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .717
Appendix 2: Reviewer Relationships With Industry
and Other Entities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .718
Preamble
This document has been developed as a health policy
statement by the American College of Cardiology (ACC),
American Heart Association (AHA), American Society of
Echocardiography (ASE), American Society of Nuclear
Cardiology (ASNC), Heart Rhythm Society (HRS), Inter-
societal Accreditation Commission (IAC), Mended Hearts,
North American Society for Cardiovascular Imaging
(NASCI), Radiology Society of North America (RSNA),
Society of Atherosclerosis Imaging and Prevention (SAIP),
Society for Cardiovascular Angiography and Interventions
(SCAI), Society of Cardiovascular Computed Tomography
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(SCMR), and the Society of Nuclear Medicine and Molec-
ular Imaging (SNMMI). This document is an ACC health
policy statement and is intended to promote or advocate a
position, to be informational in nature, and to offer guidance
to the stakeholder community regarding the ACC’s stance
on healthcare policies and programs. Health policy state-
ments are not intended to offer clinical guidance and do not
contradict existing ACC clinical policy. They are overseen
by the ACC Clinical Quality Committee (CQC), the group
responsible for developing and implementing all health
policy statement policies and procedures related to topic
election, commissioning writing committees, and defin-
ng document development methodologies. The CQC
rings together various areas of the College such as the
dvocacy Committee, the National Cardiovascular Data
egistry, the ACC/AHA Task Forces on Guidelines and
erformance Measurement, and the Appropriate Use
riteria Task Force. The CQC recommended the devel-
pment of this Health Policy Statement to document the
ollege’s official position on improving the effectiveness
f diagnostic cardiovascular imaging to achieve better
atient outcomes.
To avoid actual, potential, or perceived conflicts of
nterest that may arise as a result of industry relationships or
ersonal interests among the writing committee, all mem-
ers of the writing committee, as well as peer reviewers of
he document, are asked to disclose all current healthcare-
elated relationships, including those existing 12 months
efore initiation of the writing effort. The ACC CQC
eviews these disclosures to determine what companies
ake products (on market or in development) that pertain
o the document under development. On the basis of this
nformation, a writing committee is formed to include a
ajority of members with no relevant relationships with
industry (RWI), led by a chair with no relevant RWI. Authors
with relevant RWI are not permitted to draft or vote on text or
recommendations pertaining to their RWI. RWI is reviewed
on all conference calls and updated as changes occur. Author
and peer reviewer RWI pertinent to this document are dis-
closed in Appendices 1 and 2, respectively. Additionally, to
ensure complete transparency, authors’ comprehensive disclosure
information—including RWI not pertinent to this docu-
ment—is available online (see Online Appendix 3). Disclosure
information for the ACC CQC is also available online at
www.cardiosource.org/ACC/About-ACC/Leadership/
Guidelines-and-Documents-Task-Forces.aspx, as well as the
ACC disclosure policy for document development at
www.cardiosource.org/Science-And-Quality/Practice-
Guidelines-and-Quality-Standards/Relationships-With-
Industry-Policy.aspx.
The work of the writing committee was supported
exclusively by the ACC without commercial support. Writ-
ing committee members volunteered their time to thiseffort. Conference calls of the writing committee were
confidential and attended only by committee members.
Joseph P. Drozda, Jr., MD, FACC, Chair
ACC Clinical Quality Committee
1. Introduction
1.1. Document Development Process
1.1.1. Writing Committee Organization
The writing committee consisted of a broad range of
members representing 15 societies and the following areas
of expertise: general cardiology, interventional cardiology,
pediatric cardiology, echocardiography, atherosclerotic im-
aging, cardiac computed tomography (CT), cardiac mag-
netic resonance, nuclear cardiology, electrophysiology, radi-
ology, practice administration, primary care, and patients/
consumers in order to provide an appropriate balance of
perspectives. Geographic distribution of members crossed
most U.S. time zones and included Canada. Authors
represented both academic and private practice settings.
This writing committee met the College’s disclosure re-
quirements as described in the Preamble.
1.1.2. Policy Statement Development
The writing committee convened by conference call and
e-mail to finalize the document outline, develop the initial
draft, revise the draft per committee feedback, and ulti-
mately sign off on the document for external peer review. All
participating organizations contributed to peer review, re-
sulting in 37 reviewers representing 320 comments. Com-
ments were reviewed and addressed by the writing commit-
tee. A CQC liaison served as lead reviewer to ensure that all
comments were addressed adequately. Both the writing
committee and the CQC approved the final document to be
sent for board review. Organizations reviewed the docu-
ment, including all peer review comments and writing
committee responses. The ACCF Board of Trustees ap-
proved the document August 2013. The AHA, ASE,
ASNC, HRS, IAC, Mended Hearts, NASCI, RSNA,
SAIP, SCAI, SCCT, SCMR, and SNMMI endorsed the
document January 2014. This document is considered
current until the CQC revises it or withdraws it from
publication.
2. Purpose of This Health Policy Statement:
Overview of the Issues
Medical imaging is an exemplar of the power of scientific
understanding to revolutionize the diagnosis and treatment
of disease. Using modern diagnostic techniques, physicians
can peer deeply into the body to gain insights into the
structure and function of any organ without the risks of
surgery or invasive procedures. Cardiovascular imaging
methods, including echocardiography, nuclear cardiology
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sion tomography scanning), magnetic resonance imaging
(MRI), and CT are all now routinely employed in the care
of patients. These developments would be viewed as strong
empirical evidence of the benefits society can reap from
investment in medicine but for 2 factors. First, although
imaging technologies offer the promise of more rapid and
precise diagnosis, which may result in improved patient
management, the pace of innovation and its dissemination
into practice has outstripped the ability of researchers to
define the associated incremental value clearly and persua-
sively. Second, rates of growth have previously been docu-
mented in the use of most common imaging studies
performed in the United States, particularly between 1999
and 2006, which appeared to have been driven by something
other than changes in the healthcare needs of the patient
population. These high rates of diagnostic imaging test use
coincide with a growing intensity of concern nationally
about the overall growth in the rate of medical spending in
the United States. Some of the most common cardiovascu-
lar imaging procedures, including echocardiography and
SPECT nuclear cardiac scans, have consistently ranked in
recent years in the top 200 codes billed to Medicare each
year (1). The purpose of this document, in part, is to
contend that policy decisions based on simplistic causal
models connecting these sorts of trends will yield bad policy
that may harm patients. Instead, we contend that, in order
for policy reforms to achieve their intended goals without
major off-target consequences, policy makers must take
account of the complex interplay between medical care
quality (of which proper use of diagnostic testing is an
integral part), patient health outcomes, and medical costs.
2.1. Current Understanding of Patterns of
Cardiovascular Diagnostic Imaging Use
Our understanding of the changes that have occurred over
time in patterns of care employing imaging is incomplete.
The current share of spending devoted to medical imaging
is small (about 3% of the Medicare budget in 2007), and
recent figures show declines since 2006 in the volume of
imaging services provided (2,3). In the context of a growing
belief by policy makers and payers in the need for aggressive
reductions in the level of growth in health care spending in
the United States, however, other statistics showing a
disproportionate growth in the use of diagnostic imaging
procedures starting in 1999 has led to intensified scrutiny
(4). As in many other areas of medicine, this scrutiny has
revealed substantial unexplained geographic variation in
imaging use in the United States. Such variation (typically
expressed in terms of unadjusted testing rates) is not, in
itself, proof of overuse or inappropriate care. However, the
suggestion these data offer, that some regions are able to
provide care using less resource-intensive patterns of imag-
ing without evident harm to patients, has been interpreted
by some to show that higher-use areas are employing too
much care with little incremental benefit (4). Althoughintuitively appealing to those tasked with reducing overall
U.S. health spending, this line of reasoning provides
insufficient insight to be used as the basis for shaping
good policy decisions (5). Recent investigations into the
deceleration in the rate of advanced imaging use that
started in 2006 have suggested that imaging rates are best
understood as the product of a complex interplay of
healthcare system structural factors and incentives (both
positive and negative) (6,7).
2.2. Drivers of Physician Use of Diagnostic Testing
Although direct evidence is scant, some sources asserted in
2006 that 20% to 50% or more of advanced imaging studies
performed each year provided little or no benefit to the
patient (8). Other sources have reported higher use of
imaging when the treating physician also bills for the
professional or technical fee associated with the testing
(9,10). The conclusion often drawn from such data is that
financial gain was a primary driver of the overuse of imaging
in the United States. However, a more nuanced analysis
shows that the drivers of physician test-ordering behaviors
are complex and include technological, patient, physician,
payer, and health system factors, including: the improved
ability of newer imaging techniques to answer clinically
relevant questions (independent of the question of whether
ultimate patient outcomes are affected); changing patient
demographics; greater patient awareness of and demand for
the objectivity and higher certainty that imaging seems to
offer; fragmentation of care with duplication of testing at
different points in the healthcare network for a given
patient; fear of lawsuits; diminishing confidence of practi-
tioners in their abilities to make clinical assessments without
imaging confirmation; and the incentive to do more in a
fee-for-service reimbursement context (11–14).
More evidence that a financial incentive is not the only, or
even the dominant factor at play in explaining varying
national imaging rates, comes from a recently reported
pooled analysis of 6 large health maintenance organizations
(15). Between 1996 and 2010, use of CT studies increased
3-fold, use of MRI increased almost 4-fold, and use of
ultrasound increased by 70%, whereas nuclear medicine
studies decreased by a third starting around 2008. Thus,
even in an integrated health system without a financial
incentive for testing, use of some types of imaging studies
has increased substantially over the last 2 decades.
“Defensive medicine” has been cited in numerous surveys
of physicians as a major justification for overuse of imaging
studies. A Massachusetts Medical Society study in 2008
demonstrated through a statewide physician survey that
22% of plain x-rays, 28% of CT scans, 27% of MRIs, and
24% of ultrasounds were ordered for “defensive” reasons
(16). Separating explicit concerns about vulnerability to
malpractice claims from the desire to achieve diagnostic
certainty, however, is difficult. To the extent that the latter
is a significant driver of physician behavior, medical mal-
practice tort reform may have only a modest effect on the
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date on the effects of malpractice tort reform on physician
behavior and “defensive medicine” costs is very mixed
(18–23). In addition to defensive medicine and issues of
diagnostic uncertainty, the effect of patient expectations, in-
formed by news media and internet sources, on rates of test use
should be considered, but such effects are very difficult to study
empirically or indeed to quantify in any other way.
Another important, but often overlooked, driver of
greater use of testing is the shift, over the last few genera-
tions of physicians, away from reliance on the history and
physical examination and towards more reliance on “objec-
tive” data. Medicine has, in recent decades, evolved to an
“imaging intensive” practice style or culture in which use of
imaging is routine and unquestioned rather than selective
and focused. In some clinical contexts, this increased imag-
ing use provides higher quality care, but in other contexts
more use of imaging may be disconnected from measurable
improvements in patient care and outcomes. In addition, in
the U.S. healthcare system, the physician performing imag-
ing tests has the role of a service provider, with incentives
(both financial and non-financial) to provide imaging ser-
vices as requested. In contrast, in countries with more
constraints on healthcare spending and limited medical
ability, imaging physicians are often given the potentially
more adversarial role of gatekeeper (24).
2.3. Imaging and Patient Safety:
The Issue of Cumulative Diagnostic Radiation Exposure
Recently, the issue of patient risk/safety following exposure to
ionizing radiation from CT, nuclear medicine, and invasive
angiographic studies has been added to the debate about the
use of medical imaging (25–30). For imaging modalities where
the FDA has granted approval for clinical use, implying
adequate safety at the individual test level, the clinicians
ordering those diagnostic tests, in the past, had not given much
attention to the estimated cancer risk from cumulative diag-
nostic test radiation exposure. Reasons for this include physi-
cian unfamiliarity with the issues, lack of accurate methods for
tracking cumulative radiation exposures, and the very long time
intervals involved between exposure and any detectable signs of
disease (31).
These logistical difficulties, along with the millions of
subjects that would need to be followed to accumulate a
sufficient number of incident cancer cases, have hampered
attempts to define empirically the possible impact on
lifetime cancer risk following exposure to different levels of
diagnostic ionizing radiation. As a consequence, the field
has been forced to rely on extrapolations from data outside
the diagnostic radiation imaging field (particularly studies of
the Japanese atom bomb survivors), to lower exposure doses
used in medical imaging and on modeling based on largely
untestable assumptions. The “linear no-threshold” (LNT)
hypothesis has been endorsed as the model that best fits the
fragmentary data available (32). This model assumes that
there is no safe dose of ionizing radiation, when safety isdefined in terms of future cancer risk. The model suggests,
therefore, that even with the low doses used for medical
testing, projected cancer risk is a linear function of dose. A
challenge to the LNT hypothesis is that projections as to the
health impact of radiation exposure below 50 mSv have a
large degree of uncertainty. Accordingly, there has been
tremendous controversy regarding the projected cancer risk
following radiation exposure to cardiac imaging. For clinical
purposes, the incremental cancer risk projected following
radiation exposure from medical imaging has been small
(i.e., 1% incremental cancer risk). Although observational
evidence is lacking as to whether low dose exposure, such as
that with medical imaging is associated with an increase in
incident cancer, there are data on the growing cumulative
exposure of the population to diagnostic imaging. One
recent study (15) used 15 years of patient-level data from 6
large integrated health systems (covering 1 to 2 million
member-patients per year), to estimate that from 1996 to
2010, patient per capita radiation dose doubled (1.2 mSv
versus 2.3 mSv), while the proportion of patients who
received radiation doses greater than 20 mSv also doubled
(1.2% versus 2.5%) (15). The LNT hypothesis predicts that
this trend will be associated with a projected increase in
cancer cases, although the timeline to develop new cancers
and what sort of cancers will develop are still difficult to
predict. To estimate these cancer risks, a model-based
approach such as that developed by the National Cancer
Institute (33) has been developed.
In the last several years, imagers have focused increasingly
on making diagnoses with the lowest dose of radiation. In
some cases, this has allowed testing with 50% reductions
in the radiation dose while maintaining image quality
(25,27,34,35). Clinicians, sensitized to these concerns, may
also be able to substitute a study using magnetic resonance
or ultrasound for one using radiation, particularly if there is
comparable diagnostic evidence to support the use of alter-
native test modalities.
2.4. Overview of What Follows
Physicians, payers, and policy makers agree in principle that
growth in medical imaging use without reasonable evidence
of proportionate clinical benefits cannot be defended as
responsible stewardship. Healthcare leaders further agree in
principle that medical imaging should be used in a safe and
efficient manner while fostering continued technological
innovation and preserving equitable, high-quality patient
care. Less agreement currently exists, however, on how to
put those principles into practice. The purpose of this
document is to provide a brief exposition of the issues
involved and the possible ways in which the medical care
system can balance responsible use of imaging with patient
safety concerns while maintaining or even enhancing quality
of care. The concepts, tools, and major options for achieving
those goals are the subjects of the next 2 sections. We then
consider the application of these tools for identifying and
reducing underuse (Section 5) and overuse (Section 6) of
703JACC Vol. 63, No. 7, 2014 Mark et al.
February 25, 2014:698–721 HPS on Use of Noninvasive CV Imagingimaging. We conclude with some thoughts about possibil-
ities for future initiatives.
3. Improving Imaging Use:
Conceptual Overview
The current debate on the value, safety, and quality of
medical imaging is not the product of recent insights by
clinicians, payers, or policy makers. The concerns reviewed
in the preceding section have appeared in literature dating
back more than 25 years. If nothing else, this history serves
as a warning that the issues involved are not amenable to
easy solutions. It is tempting to propose that the goal in the
field of diagnostic imaging should be to define the “optimal”
level of imaging use in practice, neither too much (which is
wasteful by definition) nor too little (which may be harmful
to patients who fail to receive the correct diagnosis or
treatment). This goal is captured in the aphorism “the right
test on the right patient at the right time” (36). However,
optimization of the sort referred to here, essentially the
“best” solution possible, only becomes operationally tracta-
ble after creating clear boundaries for the problem at hand:
a limited and explicitly specified healthcare budget allocated
to improve the health of a well-defined population, with
high-quality information on the incremental costs and
benefits of all relevant management options. In such a
context, it may be possible to identify the most efficient
patterns of testing to use in maximizing well-defined health
goal(s) with the funds available. Without such constraints,
the problem has no meaningful “optimal” solution. The
United States is clearly not willing to spend an unlimited
amount of money on health care overall, or on diagnostic
imaging in particular, but the real limits on spending and
resource allocation are not clear. For this reason, calculation
of optimal use rates for a given region or health system, or
the country as a whole, is not possible without first reaching
agreement on a large number of key assumptions.
Two general approaches have been developed to address
the questions raised by the clinical deployment of more and
better diagnostic tests: technology assessment and appropri-
ate use. Both assume that imaging in question is performed
well and interpreted accurately. Technology assessment
examines the impact of healthcare technology in a broad
policy context built around the question “what do we
know?” from all the evidence available about a particular test
or type of care. Appropriate use addresses the question
“what should we do (and not do)?” Quality improvement
integrates information from both these areas to ask a third
question “how can we improve what we do so as to provide
patients the full benefit of what we know?” In the next
section, we will examine how these 3 elements interact to
produce an operational path toward understanding “opti-
mal” imaging use. However, to place this discussion in
proper context, we first review the unique challenges pre-sented by the clinical context in which diagnostic testing
takes place.
As medicine has moved from a cottage industry of
independent physician practitioners to an increasingly cor-
porate industry accounting for 17% of the U.S. economic
output, business concepts have been imported into the
medical world with varying degrees of success. In the part of
the business world concerned with producing consumer
goods, quality is typically achieved through rigorous stan-
dardization of production methods, minimizing variation in
the resulting product. From such a business perspective,
therefore, variations in medical care chosen for the same
patient group are viewed as evidence of poor quality.
However, what this business-inspired analysis fails to ac-
count for is the pivotal role of uncertainty in every aspect of
medical practice (37). Uncertainty is present when the
physician first encounters the patient, and it remains present
throughout every aspect of the diagnostic and treatment
phases. Although uncertainty may be reduced, it can never
be eliminated. Physicians spend their professional lives
dealing with risks and benefits that can be measured only in
terms of probabilities. Variations in the use of testing,
therefore, are a likely consequence of the physician’s search
for a subjectively sufficient level of certainty (which includes
the desire to avoid diagnostic mistakes that might be the
basis for malpractice allegations), coupled with variable
inefficiency in the use of test information (for example,
when heuristics or simple rules of thumb are used to
simplify complex decisions), and the local availability of
different testing technologies and expertise. Many of these
factors taken collectively can be conceptualized as “practice
styles” that help clinicians make complex decisions effi-
ciently in situations characterized by high uncertainty and
insufficient high-quality evidence (38). Patient expectations,
and physician understanding of those expectations, may also
exert a powerful influence on testing patterns. Recognizing
this, when new policies are proposed to address perceived
overuse of diagnostic imaging, we must ask whether such
policies adequately confront the central importance of man-
aging uncertainty in patient care and the role that diagnostic
tests serve for physicians and patients in that function.
4. Improving Imaging Use:
Approaches and Tools
As discussed in the previous section, we can approach the
general problem of improving imaging use through 3 related
questions: what do we know from the available evidence?
(technology assessment), what should we do (and not do)?
(appropriate use), and how can we improve what we do so
that patients can benefit from what we know? (quality
improvement). In this section, we will examine each of these
questions and the associated pathways to answering them in
more detail. One caveat should be offered at the outset.
Each of these topics is complex and has generated an
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some general guidance through this area without any claim
to being exhaustive.
4.1. Technology Assessment
Technology assessment in the healthcare context refers to a
comprehensive, systematic evaluation of all relevant out-
comes (including clinical, economic, social, organizational,
and ethical) consequent to deploying a given health tech-
nology in a particular health system. It includes, but is not
limited to, what is now referred to as “comparative effec-
tiveness.” Diagnostic imaging technologies pose particular
problems for technology assessments because they have few
direct effects on patient health outcomes (aside from imme-
diate test-related complications). More often, diagnostic
tests provide clinicians with information that sometimes,
but not always, affects patient outcomes. Such a multilink
chain of causation stretching from the imaging tests to
patient outcomes highlights the many events that must
occur sequentially for the potential of diagnostic testing to
be realized in practice. That events chain is tightest in the
acute care setting when diagnostic testing is used to make
treatment decisions that are highly time sensitive. Of course,
even a very accurate diagnostic test is of limited value to
patients if physicians do not have the understanding or the
tools to use its results to improve care.
A 6-level hierarchical technology assessment framework
was first proposed by Fineberg et al. in 1977 for studying the
impact of imaging technology on the healthcare system and
was refined by Fryback and others several years later (39,40).
In the ideal world of “rational” health care envisioned in this
model, a comprehensive technology assessment of a new
diagnostic technology would be performed covering all 6
levels before the technology was released into general
medical practice. Such information would then help clini-
cians, payers, and policy makers understand how best to use
the new technology to provide more clinically effective,
more cost effective, higher-quality care. Nonetheless, that
ideal has never been achieved, perhaps in part because the
cost of generating the evidence to achieve such an under-
standing before general dissemination of the technology
would make innovation prohibitively expensive. The coun-
terargument is that failure to properly evaluate new technology
before widespread dissemination can lead to excessive costs and
reduced health outcomes despite the superficial appearance of
being both compassionate and innovative. Regardless of
one’s perspective on this issue, the technology assessment
framework is useful for its organizing concepts and for
pointing out the important gaps in our current understand-
ing (Table 1). Level 1 of this evaluation system addresses the
technical quality of the images (including spatial and tem-
poral resolution where relevant). Level 2 provides evidence
on the diagnostic accuracy of the test relevant to appropriate
reference standards, assessed using parameters such as sensi-
tivity and specificity, post-test probabilities, receiver-operating
curves, likelihood ratios, and interrater reliability estimates.A sizeable proportion of the voluminous literature on
evaluation of diagnostic testing falls into this category. Level
3 deals with the effect of the test on the clinician’s thinking,
particularly the incremental value of the test information in
arriving at a diagnosis. The fourth level of this evaluation
framework is concerned with the incremental effects of the
test results on the clinician’s therapeutic decision making in
the face of other available clinical information. Research in
this area is difficult to design and perform due to difficulties
in determining in what ways the physician’s reasoning
process, which cannot be directly observed, is affected by any
specific information derived from an imaging test. The final
2 levels of this technology assessment hierarchy framework
evaluate the effects of testing on incremental patient out-
comes (including safety-related outcomes) and whether the
use of the test is cost effective from a societal perspective.
Effects of testing strategies on patient outcomes should be
ideally assessed in a randomized trial, but such trials are
difficult to perform, expensive, and have been very rarely
attempted. Several randomized trials have recently evaluated
the effects of coronary computed tomography angiography
on management of patients with acute chest pain. The focus
of these initial studies has been on efficiency and cost of
care, and data on long-term patient outcomes have not
typically been included, although additional outcome-based
studies are currently underway (41–43). Cost-effectiveness
models of diagnostic testing strategies are simpler to per-
form than randomized trials, but modeling by itself does not
resolve the underlying uncertainties involved in translating
data on test performance into an understanding of the
comparative effectiveness of alternative testing strategies, for
which there is usually only limited and lower-quality evi-
dence (44,45).
4.2. Appropriate Use of Testing
The concept of appropriate use applied to medical care
shares many of the conceptual and operational difficulties
encountered in defining an “optimal” rate or pattern of
medical care (46). All the definitions in the literature make
reference to positive health benefits for the patient, but
without further specification, this is of limited utility. The
RAND/UCLA Appropriateness Methodology was origi-
nally developed in the 1980s as part of a series of studies on
the overuse and underuse of medical and surgical procedures
(47). According to RAND: “An appropriate procedure is
one in which “the expected health benefit (e.g., increased
Table 1. Hierarchical Model of Diagnostic Test Evaluation
Level 1 Technical efficacy
Level 2 Diagnostic accuracy efficacy
Level 3 Diagnostic thinking efficacy
Level 4 Therapeutic efficacy
Level 5 Patient outcome efficacy
Level 6 Societal efficacylife expectancy, relief of pain, reduction in anxiety, and
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consequences (e.g., mortality, morbidity, anxiety, pain, and
time lost from work) by a sufficiently wide margin that the
procedure is worth doing, exclusive of cost” (47). This
method employs a panel of experts who are instructed to apply
their professional clinical judgment while taking account of the
available research evidence to rate appropriateness on an
ordinal scale, ranging from 1 (very rarely appropriate) to 9
(most appropriate). A 2-round “Delphi process” is used to
generate expert appropriateness ratings of medical and
surgical procedures performed in briefly defined clinical
scenarios. The expert panel is asked to base their ratings on
an “average patient” presenting to an “average clinician” in
an “average” medical care setting (47). The method seeks to
identify when consensus exists but does not force consensus.
The median scores and levels of group disagreement are
used to classify the final ratings into 3 groups: rarely
appropriate, uncertain, or appropriate.
RAND appropriateness methods were first applied to
medical imaging by the American College of Radiology
starting in 1993 (48). The ACC, in conjunction with the
ASNC, applied these methods to cardiovascular nuclear
stress tests in 2005. To adapt the RAND appropriateness
methods to the problem of diagnostic imaging, an ACC
expert panel proposed a modified definition of appropriate
use: “an appropriate imaging study is one in which the
expected incremental information, combined with clinical
judgment, exceeds the expected negative consequences [in-
cluding the risks of the procedure and the downstream
impact of false-positive and false-negative test results] by a
sufficiently wide margin for a specific indication that the
procedure is generally considered acceptable care and a
reasonable approach for the indication” (49). Appropriate
use of testing is thus acknowledged to rest heavily on the
clinical judgment that performing the test in question for
the indication in question would “be an acceptable step in
providing good clinical care.” More recently, the ACC also
adapted the 3 categories of appropriate use to clarify their
intent and emphasize their application to populations. The
new category labels are: appropriate, maybe appropriate, and
rarely appropriate (50).
The initial ACC appropriate use criteria document in-
cluded ratings for 52 possible indications for myocardial
perfusion imaging (49,51). Empirical testing of these crite-
ria in an academic medical center using patients enrolled
before the appropriate use criteria were published found that
64% of tests were appropriate, 11% were uncertain, 14%
were rarely appropriate, and 11% were not classifiable
(52). A follow-up study from the same laboratory reflect-
ing the period after the appropriate use criteria were
published showed lower rates of rarely appropriate studies
to 7%, but could not identify the cause of this improve-
ment (53). In that academic center, the specialty of the
ordering provider did not affect the rate of appropriate
testing (54); but in earlier studies, physician specialty,experience, and practice environment did affect appropri-
ate use of coronary angiography (55).
Although much current attention is directed to overuse of
advanced imaging studies, 1 of the original motivations for
the RAND appropriateness work was to identify underuse
of effective care. The RAND investigators introduced the
concept of necessity, defined as “care that must be offered,”
to assist in the identification of underuse (47). Underuse has
been identified as a problem disproportionately affecting
minorities, women, and the poor, and is likely to result in
worse health outcomes (56–58). Underuse of appropriate
coronary revascularization, for example, has been associated
with higher cardiac event rates and worse angina control
(59,60). Demonstrating that underuse of advanced imaging
has had a negative effect on health outcomes would be
substantially more difficult because, as noted earlier, these
effects are indirect. Thus, although some observational data
suggest that lower use of echocardiography among patients
with newly diagnosed heart failure is associated with lower
use of evidence-based medications, the nature of the con-
nection between the performance of the diagnostic test and
the treatment decisions remains uncertain in the absence of
a randomized trial (61–63).
Appropriate use criteria have been critiqued for having
only fair reproducibility among different rating panels,
particularly in areas where evidence is weaker (64). Repro-
ducibility of appropriate ratings, however, appears to be
comparable to reproducibility of interpretations for cardiac
imaging tests (65). The Delphi approach used in developing
the criteria is reasonable for common conditions where all
the important elements can be easily summarized, but
would not be expected to capture important nuances of care
that might modify decisions for individual patients. The
pervasive uncertainty that characterizes medical practice
creates unresolvable ambiguities in what will and should
be considered appropriate care (66). Appropriate use crite-
ria, therefore, are best considered “rules of thumb” that work
reasonably well in groups of patients but may fail to capture
important aspects of testing decisions for individual patients
(6). For this reason, “rarely appropriate” should not be
viewed rigidly as synonymous with negligent care or mal-
practice. A useful distinction, therefore, may be made
between appropriate use criteria applied to individual pa-
tients versus a large group of patients. Individual deviations
from “appropriateness” are to be expected and should not be
viewed on this basis alone as evidence of poor-quality care.
A good decision process that led to a choice for “rarely
appropriate” care should be explainable and reasonably
transparent so that the unique features of the case are
evident and it is clear that no major reasoning error was
involved. Some level of “rarely appropriate” care is to be
expected in even the best practices, and elimination of these
cases may harm patients with less common presentations
and features.
Early investigations on the relationship between appro-
priate use ratings and geographic variations in patterns of
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did not usually have higher rates of rarely appropriate care
(67). In fact, much of geographic variation in care occurs
within the category of appropriate care and presumably
reflects different assessments by physicians about the incre-
mental value of that care for individual patients. Other
important drivers of geographic variations in care include
differences in practice “styles” (shaped by heuristic patterns
of care used to simplify and speed up complex decision
making, as well as peer practice norms for the community in
question) and technology diffusion (66,68). Little work has
been done to date on the relationship between appropriate
use ratings and cost effectiveness (incremental health bene-
fits as a function of incremental medical costs). Cost was
excluded from consideration in the RAND appropriateness
method, although implicitly considered in ACC efforts. The
contention, by payers and some policy makers, that 20% to
50% of advanced imaging studies provide little to no benefit
implies that they are including in that estimate not only the
10% to 20% of studies that typically are judged as not being
appropriate but a significant proportion of other studies that
are currently deemed reasonable. However, since this issue
has not been studied, the actual amount of cardiovascular
imaging that would fall into this latter category (appropriate
but for which its value is highly variable based on context) is
currently unknown (69).
4.3. Quality Framework for Diagnostic Imaging
Quality of care as it relates to imaging refers to the use of
available best evidence to provide safe and effective man-
agement for patients with clinical problems where imaging
has an important role to play. Quality in this context is most
often operationalized using the 3-element model first pro-
posed in 1966 by Donabedian: structure, process, and
outcome (70–72). Applied to imaging, the specific compo-
nents of each element are chosen for their relationship to
safety or to clinical management. Structure includes the
infrastructure that is required to support the performance of
imaging studies, such as properly functioning state-of-the-
art equipment and facilities, certified staff and physicians,
continuous quality initiatives/maintenance of certification/
training/continuing education for all members of the team,
and use of imaging society standard imaging protocols and
standardized reporting software. Process starts with patient
Figure 1. Dimensions of Care Framework for Evaluating QualityReprinted with permission from Douglas et al. (8).evaluation and referral, and includes clinical decision mak-
ing, standardized imaging acquisition, standardized test
interpretation and report generation, communication of
meaningful results, and test result–guided patient manage-
ment. Outcomes include all the consequences of testing,
both direct and indirect, that affect patients, including
morbidity, mortality, quality of life, satisfaction, and cost.
Traditionally, quality assessment in imaging has been lim-
ited to considering structure and some elements of process
alone. New models of imaging quality seek to improve the
entire processes of care, and consequently health outcomes,
through a systematic focus on each link in the diagnostic
imaging chain from test ordering to the communication of
and use of the results (Figure 1) (8). Selected elements in
this chain are considered in greater detail in the following
text.
4.3.1. Quality Improvement of Imaging:
Laboratory Accreditation
Accreditation of laboratories and certification of personnel
who perform and interpret imaging (considered in the next
section) are structural quality elements in the conceptual
quality model presented in the previous section. The U.S.
Congress, in its Medicare Improvements for Patients and
Providers Act of 2008, mandated that as of January 1, 2012,
all non-hospital entities supplying the technical component
of advanced imaging services (defined as MRI, CT, nuclear
medicine, and positron emission tomography) must be
accredited by an approved organization in order to receive
reimbursement. The 3 accreditation organizations approved
by the Centers for Medicare and Medicaid Services (CMS)
for this purpose are the Intersocietal Accreditation Com-
mission (IAC), the American College of Radiology (ACR),
and the Joint Commission (5). For other imaging modalities,
such as echocardiography, accreditation is currently still volun-
tary for CMS reimbursement. However, some private payers
have had similar payment policy requirements in place for
several years and have included echocardiography (73).
With respect to IAC accreditation, the process of obtain-
ing and maintaining accreditation requires a commitment to
continuous compliance with peer-derived imaging stan-
dards. Representatives of those professional societies who
are stakeholders in the specific imaging modality being
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laboratories. Depending on the baseline level of laboratory
organization, the initial accreditation process for some may
prove to be a time consuming and labor intensive process,
Specific protocols must be written, implemented, and mon-
itored to meet and maintain compliance with accreditation
standards. Once obtained, the process of maintaining ac-
creditation requires commitment to continuous compliance
with imaging accreditation standards thus making future
accreditations relatively simple.
The application requirements covering structure include
1) a facility overview; 2) estimates of annual procedure
volumes; 3) details of staff experience, training, and creden-
tials; and 4) an imaging equipment list. The facility over-
view involves documentation of administrative policies for
patient confidentiality, patient complaints, infection con-
trol, drug and contrast administration policies, emergency
equipment, medication control, and other safety policies
specific to the imaging modality (e.g., cardiac life support
certification). The application for accreditation also assesses
critical elements of process such as, patient identification
and pregnancy screening (e.g., what steps are taken to
ensure that the correct patient is tested), radiation and other
safety protocols (as applicable), quality control protocols and
quality improvement for the imaging equipment, and the
use of standardized and timely reporting. Outcome of
maging is assessed in a limited way through documentation
f ongoing quality improvement activities. These activities
nclude measurement of appropriate use and patient satis-
action, technical and interpretative review, correlation with
ther imaging modalities, and patient outcomes.
The final step of the application process includes the
ubmission of case studies (generally ranging from 3 to 6
ases [but up to 12 for large echocardiography or general
uclear medicine laboratories] performed within 1 year of
he application). Independent peer review assessment of the
nterpretive and technical quality of the laboratory is per-
ormed. Once submitted, the application review typically
akes 10 to 14 weeks (74).
IAC accreditation reflects demonstrated adherence to
omprehensive imaging standards, authored by profession-
ls within the imaging community. Detailed internal exam-
nation, coupled with external peer feedback, constitute
AC’s foundational approach to quality, assessment, and
mprovement. Active engagement in these processes is
xpected to improve laboratory quality. That stated, it must
e recognized that IAC (or any accrediting organization) is
ot a governmental agency and does not hold regulatory
uthority.
Potential weaknesses of IAC’s approach to accreditation
nclude its reliance on self-selected cases and limited audits
f data submitted. Furthermore, because accreditation is a 3
ear process with 1 mid-cycle audit, compliance cannot be
ssessed on an ongoing basis at this time. Efforts are
urrently underway within IAC to review solicited cases
ather than self-submitted cases. Expansion of standards toinclude collection of prospective data on appropriate use,
ensuring a more robust internal peer review process, and
specific radiation safety practices represents efforts to keep
accreditation robust and relevant. Further, IAC has initiated
a program of research to demonstrate the value of accredi-
tation in improving clinical quality). Standardized report-
ing, with emphasis on consistency and clarity has been
shown to help avoid redundant testing (8). Recent literature
has suggested that IAC requirements for standardized
reporting have increased accuracy rates and created a more
uniform performance among laboratories in subsequent
accreditation cycles (9). Data are not yet available on the
impact of reduced reimbursement and increased adminis-
trative burden from pre-authorization/notification require-
ments on laboratory quality.
4.3.2. Quality Improvement of Imaging:
Physician Certification and Credentialing
Physician certification is another structural method of ad-
dressing imaging quality. Imaging societies, including the
ASE, ASNC, ACR, SCCT, and SNMMI, have created
physician board certification for specific imaging modalities.
The first cardiac MRI certification examination is antici-
pated in 2015. The American Board of Radiology is pilot
testing a focused practice evaluation in cardiac CT as part of
their maintenance of certification program. In the future,
these societies are expected to broaden their curricula to
include more emphasis on appropriate use of imaging and
on basic principles underlying the use of multiple modali-
ties.
4.3.3. Quality Improvement of Imaging:
Integration of Care and Accountability
Efforts to assess quality and appropriate use have typically
focused on the imaging laboratory, but use of cardiac
imaging depends on actions taken by referring physicians
and patients, as well as by imaging laboratory staff. Prior to
testing, the referring physician must correctly identify which
patients need imaging, and in those patients, he or she must
select a specific test. After the test is ordered and the patient
appears in the laboratory for testing, the physician who
oversees the imaging assumes responsibility, which includes
standardized image acquisition and protocols, processing,
and reporting. The reading physician must interpret the
images, generate a report, and convey the test results and
their relevance to the referring physician. At this point, the
responsibility returns to the referring physician who must
incorporate the results into the care of the individual patient
and formulate patient management strategy based on test
results.
The process of ordering, performing, and interpreting
imaging tests and acting upon the results underscores the
concept that quality improvement must address the entire
process of care and not focus only on the imaging labora-
tory. Thus, development of metrics reflecting performance
at each of the steps of the process is needed, but, at present,
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the complex factors that influence post-test management
practices by referring physicians (Figure 1). The burden and
cost of additional data collection, however, must be carefully
weighed against its incremental value. At the step of initial
physician referral, metrics capturing information regarding
the clinical profile of patients referred to testing (e.g.,
primary reason for referral, distribution of patient pre-test
likelihoods of coronary artery disease) could characterize
patient selection and choice of imaging method and be used
to calculate appropriate use criteria. However, a detailed
clinical history is often not collected at the time of patient
referral to an imaging laboratory. Thus, such data are usually
not available in imaging databases. The second step could
assess quality metrics for image acquisition and reporting
established by the various imaging societies, which is the
most readily available electronically stored data. The final
step could involve determining how test results were used to
guide the clinical management of patients (e.g., changes in
medical therapy, referral for invasive catheterization). Cur-
rently, most practice sites lack the needed infrastructure to
make routine tracking of outcomes that result from testing
feasible. Eventually, patient outcomes could also be docu-
mented. The ability to link patient baseline characteristics
with test performance and result data and patient outcomes
would allow for the construction of longitudinal databases.
Such data resources could be used to examine some com-
parative effectiveness questions related to the association
between testing strategies and long-term outcomes.
Nevertheless, sizeable challenges exist for the develop-
ment of integrated longitudinal registries incorporating
imaging with other patient information. As an example,
ASNC’s ImageGuide™ registry is proposing to rely on
interpretive software programs that are based on standard-
ized reporting for data elements. Yet, the clinical data will
be insufficient for documentation of the gamut of AUC
indications. As such, adaptations are required to minimize
data entry and limit AUC to those rarely appropriate
indications that have been highlighted in the American
Board of Internal Medicine’s Choose Wisely program.
Although plans are underway to link ImageGuide to the
ACC’s CathPCI registry and possibly to payer databases,
the inclusion of long-term outcomes has not been proposed
due to the excessive burden that this would place on
participating laboratories. Expansion of the ACC’s data
registries into the outpatient area, along with the increase in
health system based electronic health records will provide
the basis for future such efforts.
5. Identifying and Reducing Underuse of
Cardiac Imaging
Underuse of imaging is an extremely difficult concept to
operationalize. As a practical matter, if the role of a
diagnostic test is to reduce the uncertainty of a clinicianto the point where she or he is able to decide on a course
of management most likely to relieve suffering and
improve outcomes, identifying when a test should have
been done but was not becomes very difficult, inasmuch
as it depends on the unobservable reasoning processes of
the clinician as well as their unspecified, personal toler-
ance for diagnostic uncertainty. When applied to the
problem of underuse, the RAND Appropriateness
Method had to be adapted by the introduction of the
concept of necessity: procedures and therapies that must
be offered (47). The difference between appropriateness
and necessity is that the latter reflects the judgment that
patients have a clinically important probability of being
harmed by the failure to perform the test or administer
the treatment in question. By contrast, appropriateness
only indicates a judgment that a course of action has a
favorable risk/benefit ratio, but it is possible that not
doing the test or doing a different test may also be
appropriate by the same benchmark. Failure to adminis-
ter aspirin to an acute coronary syndrome patient can be
expected to be harmful on average, based on a large body
of clinical trial evidence (75,76). Failure to perform an
exercise myocardial perfusion single-photon emission
computed tomography or a cardiac MRI scan in a certain
circumstance has consequences that are much harder to
define, in part because they are conditional on a large
number of other factors. The consequences, for example,
may be different if the alternative being considered is no
testing versus performance of exercise treadmill testing
or a cardiac stress transthoracic echo. There are few
empirical data that persuasively document harms from
the omission of imaging studies. Consequently, defining
clinical scenarios that meet the RAND necessity criteria
in the case of diagnostic imaging is quite difficult. A
second method of identifying underuse employs selection
of benchmarks from observational data. By comparing
groups assumed to be similarly situated in terms of
opportunity for benefit and assuming that greater rates of
use are beneficial, it can be inferred that lesser rates are
therefore harmful. For example, if the rate of cardiac
imaging in white males is assumed to reflect a reasonable
benchmark for necessary care, lower rates observed in
women and minorities would be interpreted as underuse
and would be expected to lead to poorer health outcomes.
The difficulty with this approach is that there is often
little justification supporting the benchmark upon which
the whole analysis rests.
True underuse of cardiac imaging occurs for at least 3
general reasons: 1) reduced access to care due to eco-
nomic, geographic, or cultural barriers; 2) inadequate
understanding by physicians of the potential value of
cardiac imaging to guide therapy and thereby improve
quality of care; and 3) poor integration of the healthcare
delivery system. Determination of left ventricular func-
tion by imaging in patients with heart failure has been
recognized in practice guidelines as an important step in
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tracked as a quality measure, but few other uses of
noninvasive imaging have established a direct connection
to patient outcomes supporting the case for harm from
less testing. At present, there are no large-scale system-
atic efforts to quantify underuse of medical imaging and
identify potential remedies. Large clinical trials (e.g., the
PROMISE [Prospective Multicenter Imaging Study for
Evaluation of Chest Pain] [77] and ISCHEMIA [Inter-
national Study of Comparative Health Effectiveness
With Medical and Invasive Approaches] [78] Trials)
could provide a path to identifying underuse by defining
the clinical circumstances in which specific testing strat-
egies improve outcomes. Underuse could then be opera-
tionally defined as the absence of testing in those clinical
circumstances, without need to refer to the physician’s
level of uncertainty or to select unproven benchmarks.
However, most clinical decisions involving imaging are
unlikely to be the subject of large-scale clinical trials.
Consequently, inferences about the best role of testing
(including when failure to test would be harmful to
patients) will still often need to be made from careful
analyses of suitable observational data.
Cardiovascular imaging to assess the structure and
function of the heart is often critical to the successful
management of many cardiovascular disorders. Despite
an understanding of the 3 potential causes of underuse as
described above, it is important that future systems of
care employ current and emerging technology to assist
consultants in their use of imaging. Such technologies
might include electronic health record and clinical deci-
sion support systems that review patient data and provide
alerts and reminders concerning diagnostic tools available
based on the current diagnosis and clinical course.
Emerging office-based and hospital-based systems may
allow practitioners in the future to better serve disparate
populations and those where language and cultural bar-
riers remain an obstacle to appropriate and timely care.
6. Identifying and Reducing Overuse of
Cardiac Imaging
Payers and policy makers have focused on overuse of
advanced cardiac imaging because managing it is a way to
reduce medical costs: by definition, overuse is care that
adds cost but little or no benefits to patients. However, by
considering cost as well as net clinical benefit when
discussing “overuse” of imaging, payers and policy experts
are using a different concept from the one most com-
monly used by physicians and patients, which considers
only net clinical benefit. Greater conceptual clarity about
exactly what constitutes overuse and how it should be
measured will be necessary in order to assess the degree to
which different strategies are successful in controlling it.6.1. Payer Efforts to Control Imaging Costs:
Administrative Efforts
Payers for health care have over the last 2 decades developed
and implemented 3 main strategies to control expenditures
associated with the use of diagnostic imaging: 1) requiring
physicians to obtain prior authorization from a “radiology
benefits manager” (RBM) before performing the test in
question—favored by many private payers; 2) requiring prior
notification before performing select “high end” or advanced
diagnostic imaging tests, such as MRI and PET (the
notification process is believed by its proponents to encour-
age thoughtful test selection and does not require a formal
approval step prior to testing); and 3) reduced payments for
imaging services—favored by CMS and discussed in the
next section. These strategies have evolved in response to
the perceived absence of self-regulation by the clinical
community.
RBMs are typically independent companies that are hired
by payers to help control imaging costs. About half of all
privately insured patients currently have coverage that re-
quires prior authorization by an RBM (6). The RBMs assert
that their algorithms are based on professional society
appropriateness criteria and guidelines, but these claims can
be difficult to verify because the algorithms used are often
proprietary, and generally not available for peer review or
validation. Because of this lack of transparency, some
clinicians view RBMs as a blunt tool to reduce costs by the
indiscriminate refusal of services, rather than an effort to
improve quality of care (79). Recent congressional and state
investigations have, in fact, found that some contracts
between payers and RBMs have explicitly tied the RBM
fees to the degree of savings to the payer (80). The legality
of such direct financial incentives has been challenged in a
number of states. Use of RBMs has indeed been associated
with slower growth of utilization (81), but there are few data
assessing the effect of these programs on quality of care.
Furthermore, the effects of these programs on patient access
to appropriate services remain undefined. Prior authoriza-
tion and notification adds layers into care processes, but the
net effects on the healthcare system, including downstream
costs and patient outcomes, cannot be judged without
empirical data (82). A recent study comparing appropriate-
ness use criteria for transthoracic echocardiography with
RBM preauthorization decisions found moderate to poor
agreement (83). Recently in Delaware, RBMs denied ap-
proval of nuclear stress testing in 25% of cases, but only
two-thirds of these denials were concordant with ACC
appropriate use criteria for nuclear stress testing (80). A
large proportion of the denials in this case involved a
decision by the RBM that a stress treadmill, or in a smaller
number of cases a stress echo, was sufficient. Currently,
CMS is legally prohibited from using preauthorization of
imaging, but periodically there are discussions in Congress
to eliminate this restriction. In 2011, CMS initiated a
5-center, 2-year demonstration project to determine the
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advanced selected CT, MRI, and nuclear medicine studies
(84). Cardiac imaging is represented in this project by
single-photon emission CT myocardial perfusion imaging.
6.2. Payer Efforts to Control Imaging Costs:
Use of Payment Reforms
In 2005, CMS started reducing physician payments for
some imaging services in the Medicare program. Attempts
to use reimbursement incentives to control healthcare costs
through alterations in the care process are perennially
appealing to payers, but the track record of such efforts,
going back to the price controls of the Nixon administration
(1971), is mixed at best. In addition, piecewise manipula-
tions of the healthcare system, an extraordinarily complex
interdependent sector of the economy, often induce unan-
ticipated and undesirable consequences. Reducing payment
for office-based tests relative to hospital-based tests, for
example, might seem like a logical way to reduce wasteful
spending in low-risk patients, but may have the unintended
consequence of shifting testing to a less efficient, more
expensive hospital-based laboratory (85). Similarly, reduc-
ing payment for stress echo might cause patients to be
referred more often for stress nuclear studies, which are
typically more expensive. Reducing physician fees for testing
in the past has been associated with a subsequent increase in
the volume of patients being tested (11). Finally, there is
some evidence that reduced payments for imaging studies in
physician practices have played an important role in the
major and relatively abrupt shift in the relationships be-
tween physicians and health systems. Increasing numbers of
physicians, unable to generate sufficient revenues to stay in
practice due to changes in reimbursement, have become
employees of large corporate entities rather than remaining
independent small business owners (85). The full conse-
quences of this tectonic shift in the structure of medicine on
patient outcomes and healthcare costs will take decades to
define clearly. The likelihood that physicians employed by a
hospital system will be less subject to incentives to maximize
revenue than if they were in a physician practice group
seems small in the current U.S. healthcare environment.
6.3. Appropriate Use Criteria
The challenges involved in adapting appropriate use criteria
to diagnostic imaging technologies have already been dis-
cussed. As noted earlier in this document, the development
of the RAND Appropriateness Method was motivated by
the hypothesis that empirically observed geographic varia-
tions in care were due primarily to variations in appropri-
ateness of care. Empirical investigations using this method,
however, found that appropriateness of care was not the
primary driver of geographic variations (87). Rather, most of
the variation was seen in care rated appropriate. A major
goal of many payers and policy makers is to reduce costs. To
achieve that goal without harming patient health, they can
reduce inappropriate use as far as possible. However, sinceinappropriate use rates in many studies are relatively low,
payers seeking to save substantial amounts of money must
also reduce the use of inefficient care, namely that care
classified as “appropriate” but which provides essentially no
health benefits (so called “flat of the curve medicine”).
While it may be surprising to some, appropriateness and
cost effectiveness do not measure the same thing. Thus, care
may be appropriate but not cost effective. Thus, to achieve
more efficiency in care (increased proportion of care that is
“cost effective” by conventional benchmarks), greater use of
appropriate use criteria alone will be insufficient. Further,
decision making based only on short-term costs (e.g., the
cost of imaging tests) without considering longer-term costs
and outcomes (e.g., procedures avoided, adverse events
prevented) may have the paradoxical effects of reducing both
the quality and cost effectiveness of care. At present,
however, the amount of imaging care that is “appropriate”
but low value from a cost effectiveness perspective is
unknown (14).
6.4. Clinical Decision Support Tools
As noted earlier, diagnostic testing is an adjunct to the
physician’s clinical reasoning, used primarily to reduce
uncertainty in ways that facilitate reaching a decision about
a diagnosis and consequently a management strategy most
likely to restore/maintain health and quality of life for a
given patient (88). Attempts to use computers to create or
deliver tools that will improve clinical decision-making have
been ongoing for over 40 years. These tools have taken a
variety of forms, including statistical models and prediction
rules, decision support systems, and decision analysis. De-
cision models require explicit structuring of a decision
problem and population of the model with the best data
available in order to identify key uncertainties, evaluate
options and identify the one with the best outcomes.
Sensitivity analyses allow for evaluation of the extent to
which that preferred strategy is sensitive to key starting
parameters and assumptions in the model. Decision models
are a powerful way of examining complex choices under
uncertainty but are generally too labor intensive to be
practical for real-time patient care. In the future, a library of
such models covering common clinical problems and em-
bedded in an electronic medical record platform could be
used to provide patient-specific support in even relatively
complex decisions. Statistical models and other prediction
rules are tools that “inform” the testing decision by estimat-
ing either diagnostic probabilities or patient risk. These
tools, unlike decision models, do not directly identify the
preferred decision.
Outside cardiology, there is moderate evidence for the
utility and effectiveness of qualitative and quantitative “clin-
ical decision support” rules for several specific conditions,
such as a traumatic headache (89), knee pain (e.g., Ottawa
Knee Rule) (90), and low back pain (91). The Framingham
Risk Score (92), the CHADS2 score in atrial fibrillation
(93), the Thrombolysis In Myocardial Infarction (94), and
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acute coronary syndrome are examples of cardiovascular risk
scores widely used to support specific treatment decisions.
These aids are typically based upon empirical or regression
model weighted scoring rules that contain elements of the
patient’s history, physical findings, and initial laboratory
tests selected for their ability to accurately estimate the
pretest probability of a diagnosis or outcome of interest.
Such models are, at least theoretically, more flexible than the
RAND Appropriateness Method in their ability to relate
patient-specific characteristics to the need for specific types of
testing based on risk. However, the appropriateness approach
addresses the decision directly (and the risk level indirectly)
whereas the models estimate the risk directly but do not
explicitly make a testing or treatment recommendation.
Patient-specific risk assessments based on validated mod-
els can also be used as part of an appropriateness approach,
with appropriateness of testing defined in terms of the
individual patient’s predicted risk and the tests already
performed (96). However, not all the clinical situations in
which cardiac imaging is currently used have adequately
validated models available for this purpose. In addition, as
discussed with appropriate use, connecting a certain level of
risk with the necessity of a specific strategy of testing
requires evidence that, for the most part, currently does not
exist. A given test in an intermediate-risk patient may be
“appropriate” in the sense already discussed, but it would be
difficult to define it as necessary without a full specification
of the decision problem. Finally, although this risk model–
based approach is more adaptable to specifics of individual
patients than RAND or guideline-based appropriateness
measures, uncommon patient characteristics or circum-
stances will not be adequately reflected in the models and
will still require clinical judgment.
Clinical decision support systems are programs designed
to combine knowledge and patient-specific data to enhance
healthcare processes and outcomes (97). They are often, but
not always, computer-based and support disease monitor-
ing, treatment monitoring, and/or diagnosis. Between 2000
and 2010, 33 clinical trials tested various forms of decision
support on diagnostic testing outcomes (36). Fifty-five
percent improved testing behavior overall. Four of the tested
systems attempted to reduce testing rates, and all succeeded
(none involved cardiac imaging) (98). A systematic review
of the effect of computerized provider order entry systems
with decision support on physician use of medical imaging
services suggested that such systems could improve ad-
herence to test ordering guidelines (99). Interventions
generally took the form of either education (recom-
mended imaging strategies) or decision support (struc-
tured imaging request forms assessing adherence to
accepted diagnostic testing strategies). The magnitude of
effect in these standalone applications was generally
modest (100). One system designed to support the
decision for CT pulmonary angiography in suspected
pulmonary embolism in the emergency department foundthat the use of CT decreased with the decision support
(by 20%), whereas the rate of detection of pulmonary
embolism increased modestly (101). In the outpatient
setting, use of a computerized test order entry system
with decision support substantially decreased the growth
rate of CT and ultrasound testing with a lesser effect on
MR (102). Preventing nonclinical support staff from
using the system resulted in a significant improvement in
appropriateness and a reduction in low-yield tests (103).
A recent 6-center pilot study demonstrated the feasibility
of online point-of-care/referral tracking and identification
of appropriateness of practice referral patterns for radionu-
clide myocardial perfusion imaging (104). In this popula-
tion, 14% of the studies were rarely appropriate based on the
ACC appropriate use criteria, and 5 indications accounted
for almost all of those rarely appropriate tests. Further
demonstration of the feasibility of this approach came from
a single-center pilot study on the use of a Web-based
appropriateness tool for transthoracic echo (105). Patient-
specific data were entered into the point-of-care/referral
application before testing. The data entry took about 55
seconds (range 25 to 280 seconds). Agreement between the
real-time, Web-based appropriateness assessment and sub-
sequent blinded manual assessment using medical records
was excellent. Similar findings have been reported in a
multicenter study involving 100 physicians and 472 patients
(98). An appropriate use criteria-decision support tool took
an average of 137 seconds to provide an assessment of
appropriateness of three different forms of cardiac imaging,
and its use was associated with improved rates of appropri-
ate use and decreased rates of rarely appropriate use. Such
integrated evaluations of appropriate use appear to offer a
much more efficient and less expensive process than RBM
preapproval for identifying and possibly reducing some of
the overuse in current practice while also providing feedback
and education for performance improvement.
CMS has attempted to control the initial usage of some
new imaging technologies of uncertain clinical benefit
through the use of mandatory participation in standardized
registries (e.g., fluorodeoxyglucose positron emission tom-
ography for solid tumor management). One important goal
of obtaining such registry data is to accelerate the process of
studying the interrelationships of the patient risk level, test
findings, as well as, in some cases, recommended treatment
decisions, and consequent clinical outcomes. Another goal
is to compare the ability of competing imaging techniques
to produce accurate diagnoses and to monitor the response
to treatment. Both of these goals depend on observational
strategy-of-care comparisons. Even with a rich data re-
source, the challenge of such work is considerable, due to
the lack of any theoretical or operational basis for defining
when the analysis has achieved sufficient control of con-
founding variables and when it has not. Unfortunately, use
of multivariable adjustment tools, such as propensity scores,
does not guarantee that adequate control for testing selec-
tion bias has been achieved.
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CMS has recently begun public reporting of a number of
new standardized performance measures and comparative
benchmarking of imaging study usage for U.S. hospitals for
a variety of clinical issues (106), which will include cardiac
imaging for perioperative risk assessment for noncardiac
low-risk surgery beginning in 2014 (107). Such a move may
portend the possibility of financial rewards and/or punish-
ments for performance by CMS in the near future, which
may also be used by commercial payers. However, there is
little evidence that public reporting efforts by CMS have
had any real effect on patient outcomes, particularly because
the time lag in reporting data is such that opportunities to
intervene have long passed when the data appear. With the
institution of new payment methods that utilize financial
risk for shared savings with providers, such as Medicare-
sponsored Accountable Care Organizations, bundled pay-
ments for specific diseases (such as heart failure, cardiac
surgery, and acute myocardial infarction), physicians will
likely seek to more carefully monitor and manage their use
of diagnostic imaging for the populations of patients for
which they provide clinical care. Such direct incentives for
physicians to avoid overuse of imaging studies will enhance
the demand for low-overhead point-of-care implementation
of management tools such as appropriate use criteria. Newer
methods of imaging may require evaluation and close
monitoring through special registries that track and better
define direct linkages to patient-centered outcomes through
comparative effectiveness research supported by such enti-
ties as the newly established Patient-Centered Outcomes
Research Institute (108,109).
6.6. Physician Professional Organization Initiatives
Importantly, physician groups are involved in multiple
initiatives to promote more efficient and accountable use of
cardiovascular imaging in clinical practice. The ACC has an
ongoing Formation of Optimal Cardiovascular Imaging
Utilization Strategies (FOCUS) program with the goals of
the program being 2-fold: 1) reduce geographic variation in
cardiovascular imaging through the application of the ap-
propriate use criteria; and 2) reduce rarely appropriate
testing rates. FOCUS provides an opportunity for health
plans to work with local ACC chapters on appropriate use
of imaging as part of payment reform and/or as an alterna-
tive to use of RBMs. The current FOCUS initiative has
expanded to over 800 practices/hospitals, and preliminary data
suggest that it has produced meaningful reductions in rates of
rarely appropriate testing (110,111). A number of state initia-
tives, including mandatory participation in FOCUS in Del-
aware, are underway that use the FOCUS program as a
means to drive more appropriate testing patterns. Addition-
ally, the ACC, ACR, ASE, ASNC, and the SNMMI have
also partnered with the American Board of Internal Med-
icine and Consumer Reports in the “Choosing Wisely”
initiative, which engages patients and physicians to discussthe appropriateness of testing, including cardiovascular im-
aging. Further, the American Medical Association Physi-
cian Consortium for Performance Improvement is working
to define performance measures that include the quality and
appropriate use of cardiovascular imaging procedures. Con-
tinuing to develop and implement these initiatives, and
studying their effectiveness (as reflected by outcomes and
cost) is an important direction for physician groups to
pursue to maximize high-quality health care. As part of this,
ASNC is currently embarked on registry efforts to track
appropriate use and/or radiation safety practices. An impor-
tant complementary effort is needed to develop useful tools
for shared decision making around the use of imaging
studies (109).
7. Future Directions
A national consensus has developed around the need to
improve quality and accountability in cardiovascular imag-
ing. In this document, we have reviewed the challenges
involved in finding the “optimal” rate of advanced cardio-
vascular imaging for a given region, practice environment,
or patient population. The improvement of imaging use
policy could likely benefit from an iterative process, requir-
ing relevant, high-quality data to guide continued efforts.
Clearly, policy interventions in clinical practice with the
objective of reducing overuse, underuse, and misuse need to
be supported by collection of high-quality data, from both
randomized trials and prospective registries, that capture the
complex multifactorial influences on test use in clinical practice
and how test use affects patient outcomes, and how test use
impacts both short- and long-term costs of care. As the
country moves toward universal use of electronic health re-
cords, creating and sustaining high-quality data registries may
become more feasible but concerns regarding the cost and labor
burden on imaging laboratories remain. An imaging registry
would have the greatest value if it extends beyond the bound-
aries of individual payers, health systems, and clinical special-
ties. Such a resource could be used to support both quality
improvement efforts and comparative effectiveness research.
The technology clearly now exists to permit integration of
computerized appropriate use into the processes of care so as
to create minimal provider burden and patient delay in
receiving needed care. For example, the use of automatic
data extraction from an electronic reporting system that
would seamlessly populate data elements is one means to
craft an imaging registry. However, the proper incentive
structure to promote such efforts is still not in place. In
addition, development of consensus-based data standards is
necessary before effective data pooling and analysis can take
place. The new generation of computerized decision support
tools should have the capability to create databases at each
site that can be periodically uploaded to a national cardio-
vascular imaging registry. Beyond the basic imaging data
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of patients, along with resource use data and medical costs
(not charges).
Development of computerized appropriate use tools
would be efficient and also greatly enhance transparency by
linking appropriateness ratings to a well-defined process in
which professional societies combine available evidence with
expert opinion to generate ratings that are then subject to
extensive peer review. Ideally, a computerized physician
order entry and approval process (also referred to as point-
of-care or point-of-referral tools) could automatically gen-
erate an accountability dataset, in as much as each imaging
decision will be documented by relevant clinical information
entered by the clinician responsible for the decision to test.
Such point-of-care tools would also serve an educational
function as clinicians learn by experience what indications
are rated as “appropriate” or “rarely appropriate” and why. In
addition, these tools would efficiently support imaging
laboratory quality improvement initiatives related to appro-
priate test use. The first generation of these tools would be
built on professional society–published appropriate use cri-
teria and clinical practice guidelines along with performance
and/or quality of care measures. Future generations of the
tools should be able to incorporate the option for using
patient-level risk predictions and other decision support
programs to further customize appropriate use ratings, once
these have been properly validated for clinical practice. Such
tools would also support enhanced shared decision making
discussions by giving patients and physicians patient-
specific data to consider in the decision making process.
Data collected via the point-of-care systems for the
dynamic imaging registry would support both the goals of
quality improvement and technology assessment. Evidence-
based understanding of the comparative effectiveness of new
imaging methods and technologies could be significantly
accelerated with such a resource. In addition, the relation-
ship between clinical decision making, appropriate use,
clinical outcomes, and cost effectiveness of different imaging
strategies could be empirically defined by analysis of data in
the registry. Subsequent iterations of the point-of-care imag-
ing support tools could then be evidence-based and provide
clinicians with real-time guidance about both appropriate use
(risk versus benefit) and value for money. Only by integrating
the best available evidence, while explicitly acknowledging
economic realities, can we move toward real value-based
medicine. This paradigm forms the essential underpinnings of
health technology assessments whose overarching goal is to
find the most efficient ways to employ limited medical re-
sources so as to maximize health benefits for the population.
Financial and political forces are dramatically reshaping
the practice of medicine. The resulting changes represent
both a threat and an opportunity. Many clinicians and
patients fear that imaging policy decisions will continue to
be driven primarily, if not exclusively, by cost considerations
without adequate consideration of clinical benefit and value.
Professional societies should offer a critical counterweight tosuch policies by leveraging their role as custodians of
excellence in clinical care with support for innovations that
empower physicians to better integrate quality of care with
societal value.
8. Conclusions
Use of advanced cardiac imaging raises two related policy
challenges for the profession, achieving the volume of
testing that balances patient needs and benefits with respon-
sible use of societal resources (i.e., cost effectiveness), and
continued improvement in the quality of care involving such
imaging tests. While frequently quoted statistics on the
disproportionate growth in rates of imaging suggests that
we have not always been responsible stewards of the
technology tools of our profession, more recent data shows
that the growth of advanced cardiovascular imaging has
substantially slowed since 2006, likely due to a combination
of professional society and payer initiatives. Because of
doubts of payers and policy makers about the extent to
which the profession can govern itself, blunt instruments
such as reduced reimbursement and prior notification and
authorization have been often used. These, unfortunately,
can lead to unintended consequences, such as limiting
patient access to necessary services and greater administra-
tive inefficiencies in the healthcare economy. New ap-
proaches and tools are needed that put the focus back onto
medical imaging quality of care. Validated patient-specific
point-of-care/referral appropriateness tools, and other deci-
sion support tools are examples of innovations that could
support a higher quality, more accountable use of cardio-
vascular imaging. These tools would allow physicians to
exercise expert clinical judgment, yet maintain transparency
and accountability in their use of advanced cardiac imaging
tests. Patients could be confident of getting the most
appropriate care for their individual circumstances (i.e.,
patient-centered care), and that any radiation exposure
required would clearly have a favorable risk benefit relation-
ship, while payers and policy makers would be able to
differentiate patterns of care that provide good value for
money versus patterns of care that add expense with little or
no attendant clinical benefits.
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